Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5- dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors

Journal of Medicinal Chemistry

Volumn 53, Issue 5, 2010, Pages 2136-2145

  McIntyre, Neil A ^a   McInnes, Campbell ^b,c   Griffiths, Gary ^b   Barnett, Anna L ^b   Kontopidis, George ^a,d   Slawin, Alexandra M Z ^a   Jackson, Wayne ^b   Thomas, Mark ^b   Zheleva, Daniella I ^b   Wang, Shudong ^b,e   Blake, David G ^a   Westwood, Nicholas J ^a   Fischer, Peter M ^b,d,e  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

^d UNIVERSITY OF THESSALY   (Greece)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL N [3 (NITRO)PHENYL] 4,5 DIHYDROTHIAZOLO[4,5 H]QUINAZOLIN 8 AMINE; 2 METHYL N PHENYL 4,5 DIHYDROTHIAZOLO[4,5 H]QUINAZOLIN 8 AMINE; 2 METHYL N PHENYLTHIAZOLO 4,5 DIHYDROTHIAZOLO[4,5 H]QUINAZOLIN 8 AMINE; CYCLIN DEPENDENT KINASE; N,2 DIMETHYL N (3 NITROPHENYL) 4,5 DIHYDROTHIAZOLO[4,5 H]QUINAZOLIN 8 AMINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; STRUCTURE ACTIVITY RELATION; X RAY;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASES; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 77949346933     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901660c     Document Type: Article

References (43)

1. Oelgeschlager, T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell. Physiol. 2002, 190, 160-169.
2. Sherr, C. J. Cancer cell cycles. Science 1996, 274, 1672-1677.
3. Hall, M.; Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv. Cancer Res. 1996, 68, 67-108.
4. Shapiro, G. I.; Harper, J. W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 1999, 104, 1645-1653.
5. Geng, Y.; Yu, Q.; Sicinska, E.; Das, M.; Schneider, J. E.; Bhattacharya, S.; Rideout, W. M.; Bronson, R. T.; Gardner, H.; Sicinski, P. Cyclin E ablation in the mouse. Cell 2003, 114, 431-443.
6. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3, 233-245.
7. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; Sotillo, R.; Barbero, J. L.; Malumbres, M.; Barbacid, M. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 2003, 35, 25-31.
8. Murray, A. W. Recycling the cell cycle. Cyclins revisited. Cell 2004, 116, 221-234.
9. Price, D. H. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II Mol. Cell. Biol. 2000, 20, 1619-1634.
10. Ramanathan, Y.; Rajpara, S. M.; Reza, S. M.; Lees, E.; Shuman, S.; Mathews, M. B.; Pe'ery, T. Three RNA polymerase II carboxylterminal domain kinases display distinct substrate preferences. J. Biol. Chem. 2001, 276, 10913-10920.
11. Watanabe, Y.; Fujimoto, H.; Watanabe, T.; Maekawa, T.; Masutani, C.; Hanaoka, F.; Ohkuma, Y. Modulation of TFIIH-associated kinase activity by complex formation and its relationship with CTD phosphorylation of RNA polymerase II. Genes Cells 2000, 5, 407-423.
12. Michels, A. A.; Nguyen, V. T.; Fraldi, A.; Labas, V.; Edwards, M.; Bonnet, F.; Lania, L.; Bensaude, O. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol. Cell. Biol. 2003, 23, 4859-4869.
13. Pinhero, R.; Liaw, P.; Bertens, K.; Yankulov, K. Three cyclindependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II. Eur. J. Biochem. 2004, 271, 1004-1014.
14. Kobor, M. S.; Greenblatt, J. Regulation of transcription elongation by phosphorylation. Biochim. Biophys. Acta 2002, 13, 161-175.
15. Majello, B.; Napolitano, G. Control of RNA polymerase II activity by dedicated CTD kinases and phosphatases. Front. Biosci. 2001, 6, D1358-D1368.
16. Fischer, P. M.; Gianella-Borradori, A. Recent progress in the discovery and development of CDK inhibitors. Expert Opin. Invest. Drugs 2005, 14, 457-477.
17. Koumenis, C.; Giaccia, A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol. Cell. Biol. 1997, 17, 7306-7316.
18. Fischer, P. M. The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle 2004, 3, 741-746.
19. Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; Stewart, K. J.; Wang, S.; Zheleva, D. I.; Marriage, H.; Lane, D. P.; Taylor, P.; Fischer, P.M.; Walkinshaw, M. D. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure 2002, 11, 399-410.
20. Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.; Yuill, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.; Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.-Y.; Mclnnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem. 2004, 47, 1662-1675.
21. Mclnnes, C.; Wang, S.; Anderson, S.; O'Boyle, J.; Jackson, W.; Kontopidis, G.; Meades, C.; Mezna, M.; Thomas, M.; Wood, G.; Lane, D. P.; Fischer, P. M. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem. Biol. 2004, 11, 525-534.
22. Wang, S.; Wood, G.; Meades, C.; Griffiths, G.; Midgley, C.; McNae, I.; McInnes, C.; Anderson, S.; Jackson, W.; Mezna, M.; Yuill, R.; Walkinshaw, M.; Fischer, P. M. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett. 2004, 14, 4237-4240.
23. Lehmann, G.; Luecke, B.; Schick, H.; Hilgetag, G. 2-Substituted 7oxo-4,5,6,7-tetrahydrobenzothiazoles. Z. Chem. 1967, 7, 422.
24. Bell, R. P.; Davis, G. G. Kinetics of the bromination of some enols and their anions. J. Chem. Soc. 1965, 353-361.
25. Fravolini, A.; Grandolini, G.; Martani, A. New heterocyclic ring systems from a-hydroxymethylene ketones. V. Reaction of 2methyl-6-hydroxymethylene-4,5, 6,7-tetrahydrobenzothiazol-7one with amines and amidines. Gazz. Chim. Ital. 1973, 103, 1063-1071.
26. Fravolini, A.; Grandolini, G.; Martani, A. New heterocyclic ring systems from a-hydroxymethylene ketones. IV. Reactions of 2-methyl-6-hydroxymethylene-4, 5,6,7-tetrahydrobenzothiazol-7one with semicarbazide and thiosemicarbazide leading to pyrazoline derivatives. Gazz. Chim. Ital. 1973, 103, 1057-1062.
27. Fravolini, A.; Grandolini, G.; Martani, A. New heterocyclic ring systems from a-hydroxymethylene ketones. III. Pyrazolobenzothiazoles and thiazolobenzoisoxazoles. Gazz. Chim. Ital. 1973, 103, 755-769.
28. Bredereck, H.; Effenberger, F.; Botsch, H. Acid amide reactions. XLV. Reactivity of formamidines, dimethylformamide diethyl acetal (amide acetal), and bis(dimethylamino)methoxymethane (aminal ester). Chem. Ber. 1964, 97, 3397-3406.
29. Hughes, J. L.; Liu, R. C.; Enkoji, T.; Smith, C. M.; Bastian, J. W.; Luna, P. D. Cardiovascular activity of aromatic guanidine compounds. J. Med. Chem. 1975, 18, 1077-1088.
30. Zimmermann, J.; Caravatti, G.; Mett, H.; Meyer, T.; Mueller, M.; Lydon, N. B.; Fabbro, D. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch. Pharm. 1996, 329, 371-376.
31. Katritzky, A. R.; Ostercamp, D. L.; Yousaf, T. I. The mechanisms of heterocyclic ring closures. Tetrahedron 1987, 43, 5171-5186.
32. Yin, J.; Zhao, M. M.; Huffman, M. A.; McNamara, J. M. Pd-Catalyzed N-arylation of heteroarylamines. Org. Lett. 2002, 4, 3481-3484.
33. Strekowski, L.; Harden, M. J.; Grubb, W. B., III; Patterson, S. E.; Czarny, A.; Mokrosz, M. J.; Cegla, M. T.; Wydra, R. L. Synthesis of 2-chloro-4,6-di(heteroaryl)pyrimidines. J. Heterocycl. Chem. 1990, 27, 1393-1400.
34. Lu, W.; Chen, L.; Peng, Y.; Chen, J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001, 20, 3206-3216.
35. Still, W. C.; Kahn, M.; Mitra, A. Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 1978, 43, 2923-2925.
36. McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; Fischer, P.M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang, S.; Zhelev, N.; Zheleva, D.; Lane, D. P. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (Rroscovitine). Int. J. Cancer 2002, 102, 463-468.
37. 50) of an enzymic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
38. Kontopidis, G.; Andrews, M. J. I.; Mclnnes, C.; Cowan, A.; Powers, H.; Innes, L.; Plater, A.; Griffiths, G.; Paterson, D.; Zheleva, D. I.; Lane, D. P.; Green, S.; Walkinshaw, M. D.; Fischer, P. M. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure 2003, 11, 1537-1546.
39. Leslie, A. G. W. Recent Changes to the MOSFLM Package for Processing Film and Image Plate Data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography; CCP4 and ESF-EAMCB, 1992; No.26.
40. Evans, R. R. Data Reduction. In Proceedings of CCP4 Study Weekend, 1993, on Data Collection & Processing; Sawyer, L., Isaacs, N., Bailey, S., Eds.; Daresbury Laboratory, Science and Engineering Research Council UK: Warrington, U.K., 1993; pp 114-122.
41. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
42. Lamzin, V. S.; Wilson, K. S. Automated refinement for protein crystallography. Methods Enzymol. 1997, 277, 269-305.
43. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53, 240-255.